PMID- 12574806
OWN - NLM
STAT- MEDLINE
DCOM- 20030926
LR  - 20171116
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 89
IP  - 2
DP  - 2003 Feb
TI  - Risk factors and coagulation parameters in relationship to phlebographic response 
      and clinical outcome in the treatment of acute deep vein thrombosis.
PG  - 272-7
AB  - Possible correlation of the effects of pharmacotherapy on the inhibition of the 
      in-vivo generation of thrombin and on the prevention of thrombus extension in 
      patients with deep vein thrombosis (DVT) could help to define patients at higher 
      risk. Patients with symptomatic deep vein thrombosis confirmed by phlebography 
      were randomised to intravenous unfractionated heparin (UFH), or a subcutaneous 
      low-molecular-weight heparin (reviparin) twice daily for one week, or a 
      subcutaneous reviparin once daily for four weeks. The patients were treated with 
      oral anticoagulants for at least 3 months. Main endpoints were regression of 
      thrombus on phlebography on Day 21 and recurrent symptomatic venous 
      thromboembolism up to 3 months. Coagulation parameters, markers of in-vivo 
      thrombin generation, and TFPI-release were determined at randomisation, weeks 1 
      and 3. Four hundred sixty six responders (reduction of at least 30 per cent in 
      Marder score) and 419 non-responders (Marder score unchanged or changed less than 
      +/-30%) showed no significantly different baseline characteristics. The 
      non-responder group had a higher median Marder score at baseline and after one 
      and three weeks of treatment, and had significantly higher fibrinogen levels, TAT 
      complexes and F1+2 values than responders. There were no significant differences 
      in coagulation parameters between non-responders and patients with asymptomatic + 
      symptomatic VTE with the exception of higher TAT complexes at baseline. 
      Significant differences in Marder score and coagulation parameters at baseline 
      were found between responders and nonresponders. Non-responders have a higher 
      risk tosuffer recurrent VTE and may need intensified treatment.
FAU - Breddin, Hans K
AU  - Breddin HK
AD  - International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, 
      Germany. breddin@em.uni-frankfurt.de
FAU - Kadziola, Zbigniew
AU  - Kadziola Z
FAU - Scully, Mike
AU  - Scully M
FAU - Nakov, Roumen
AU  - Nakov R
FAU - Misselwitz, Frank
AU  - Misselwitz F
FAU - Kakkar, Vijay V
AU  - Kakkar VV
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Peptide Fragments)
RN  - 0 (antithrombin III-protease complex)
RN  - 0 (fibrin fragment D)
RN  - 0 (prothrombin fragment 1.2)
RN  - 5R0L1D739E (reviparin)
RN  - 9000-94-6 (Antithrombin III)
RN  - 9001-26-7 (Prothrombin)
RN  - 9001-32-5 (Fibrinogen)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Antithrombin III
MH  - Biomarkers
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Fibrinogen/analysis
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/blood
MH  - Peptide Hydrolases/blood
MH  - Phlebography
MH  - Prothrombin
MH  - Recurrence
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Thrombophlebitis/blood/*drug therapy/epidemiology
MH  - Treatment Outcome
EDAT- 2003/02/08 04:00
MHDA- 2003/09/27 05:00
CRDT- 2003/02/08 04:00
PHST- 2003/02/08 04:00 [pubmed]
PHST- 2003/09/27 05:00 [medline]
PHST- 2003/02/08 04:00 [entrez]
AID - 03020272 [pii]
PST - ppublish
SO  - Thromb Haemost. 2003 Feb;89(2):272-7.